Xencor reported $74.33M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 541M 1000K Jun/2026
Arrowhead Research USD 140.57M 3.18M Mar/2026
AstraZeneca USD 1.55B 44K Jun/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Xencor USD 74.33M 265K Jun/2026